PI3K and cancer: lessons, challenges and opportunities

[1]  E. Hirsch,et al.  PI3K in cancer–stroma interactions: bad in seed and ugly in soil , 2014, Oncogene.

[2]  J. Pelletier,et al.  Pancreatic tumours escape from translational control through 4E-BP1 loss , 2014, Oncogene.

[3]  G. Firestein,et al.  Novel Phosphoinositide 3-Kinase δ,γ Inhibitor: Potent Anti-Inflammatory Effects and Joint Protection in Models of Rheumatoid Arthritis , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[4]  J. B. Oliveira,et al.  Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency , 2013, Nature Immunology.

[5]  Roland Seifert,et al.  Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. , 2013 .

[6]  L. Cantley,et al.  What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. , 2013, Cancer discovery.

[7]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[8]  Bonnie Tillotson,et al.  PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. , 2013, Chemistry & biology.

[9]  Nada Jabado,et al.  Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage , 2013, Science.

[10]  A. Haegebarth,et al.  BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models , 2013, Molecular Cancer Therapeutics.

[11]  B. Zingarelli,et al.  mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells , 2013, Leukemia.

[12]  S. Collins,et al.  Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. , 2013, Cancer research.

[13]  A. Angulo,et al.  Brief Definitive Report , 2022 .

[14]  T. Weichhart,et al.  Immune responses of macrophages and dendritic cells regulated by mTOR signalling. , 2013, Biochemical Society transactions.

[15]  K. Flaherty,et al.  TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma , 2013, Science Translational Medicine.

[16]  N. Rosen,et al.  mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer , 2013, Science Translational Medicine.

[17]  Jennifer S. Yu,et al.  Nuclear PTEN Controls DNA Repair and Sensitivity to Genotoxic Stress , 2013, Science.

[18]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[19]  G. Coukos,et al.  Deciphering and reversing tumor immune suppression. , 2013, Immunity.

[20]  L. Zitvogel,et al.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. , 2013, Immunity.

[21]  M. Kalos,et al.  Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. , 2013, Immunity.

[22]  J. Riley.  Combination checkpoint blockade--taking melanoma immunotherapy to the next level. , 2013, The New England journal of medicine.

[23]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[24]  C. Arteaga,et al.  Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. , 2013, Cancer research.

[25]  C. Perou,et al.  Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. , 2013, Cancer research.

[26]  Simion I. Chiosea,et al.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. , 2013, Cancer discovery.

[27]  K. Shokat,et al.  Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers , 2013, Proceedings of the National Academy of Sciences.

[28]  Peter Vogel,et al.  mTORC1 couples immune signals and metabolic programming to establish Treg cell function , 2013, Nature.

[29]  Lianfeng Zhang,et al.  eIF4B phosphorylation by pim kinases plays a critical role in cellular transformation by Abl oncogenes. , 2013, Cancer research.

[30]  D. Fruman,et al.  Targeting of the MNK–eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function , 2013, Proceedings of the National Academy of Sciences.

[31]  H. Chi,et al.  mTOR and lymphocyte metabolism. , 2013, Current opinion in immunology.

[32]  P. Houghton,et al.  Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks. , 2013, Cancer research.

[33]  Haiyan Wu,et al.  Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase , 2013, PloS one.

[34]  C. De Virgilio,et al.  Amino Acid Deprivation Inhibits TORC1 Through a GTPase-Activating Protein Complex for the Rag Family GTPase Gtr1 , 2013, Science Signaling.

[35]  G. Stamp,et al.  RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms , 2013, Cell.

[36]  P. Bastiaens,et al.  Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling , 2013, Nature.

[37]  M. Baccarini,et al.  MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance , 2013, Molecular cell.

[38]  Erin M. Coffee,et al.  Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer , 2013, Clinical Cancer Research.

[39]  Matthew Meyerson,et al.  A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1 , 2013, Science.

[40]  Han Liu,et al.  PUMA and BIM Are Required for Oncogene Inactivation–Induced Apoptosis , 2013, Science Signaling.

[41]  K. Okkenhaug.  Signaling by the phosphoinositide 3-kinase family in immune cells. , 2013, Annual review of immunology.

[42]  M. Calaminici,et al.  P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. , 2013, Blood.

[43]  A. Maitra,et al.  Phosphorylation of ribosomal protein S6 attenuates DNA damage and tumor suppression during development of pancreatic cancer. , 2013, Cancer research.

[44]  J. Tabernero,et al.  Development of PI3K inhibitors: lessons learned from early clinical trials , 2013, Nature Reviews Clinical Oncology.

[45]  K. Bhalla,et al.  Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells , 2013, Molecular Cancer Therapeutics.

[46]  M. Dimon,et al.  Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo , 2013, Proceedings of the National Academy of Sciences.

[47]  S. Grant,et al.  Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. , 2013, Cancer Research.

[48]  D. Krueger,et al.  Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma , 2013, Neurology.

[49]  Juswinder Singh,et al.  Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα. , 2013, Journal of medicinal chemistry.

[50]  Jenny C. Chang,et al.  Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. , 2013, Cancer research.

[51]  J. Fletcher,et al.  A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal. , 2013, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  R. Abraham,et al.  The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. , 2013, Annual review of pharmacology and toxicology.

[53]  Tyler T. Risom,et al.  Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models , 2013, Clinical Cancer Research.

[54]  R. Advani,et al.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  I. Flinn,et al.  GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia , 2013, Current Hematologic Malignancy Reports.

[56]  Mengrou Lu,et al.  Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function* , 2012, The Journal of Biological Chemistry.

[57]  Michael A. Davies,et al.  Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents , 2012, Clinical Cancer Research.

[58]  Roger L. Williams,et al.  G Protein–Coupled Receptor–Mediated Activation of p110β by Gβγ Is Required for Cellular Transformation and Invasiveness , 2012, Science Signaling.

[59]  N. Sonenberg,et al.  mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio , 2012, Oncotarget.

[60]  J. Burger.  Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape , 2012, Current opinion in oncology.

[61]  P. Pandolfi,et al.  Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.

[62]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[63]  W. Wilson,et al.  Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. , 2012, Blood.

[64]  C. Sander,et al.  Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.

[65]  A. Letai,et al.  Targeting the B-cell lymphoma/leukemia 2 family in cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  P. Finan,et al.  TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. , 2012, Molecular cell.

[67]  M. Gold,et al.  Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies , 2012, Front. Immun..

[68]  Lei He,et al.  PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. , 2012, Cancer discovery.

[69]  R. Siebert,et al.  Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. , 2012, Cancer cell.

[70]  D. Dominguez-Sola,et al.  Burkitt lymphoma: much more than MYC. , 2012, Cancer cell.

[71]  L. Staudt,et al.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.

[72]  Y. Maehara,et al.  Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny , 2012, Cancer and Metastasis Reviews.

[73]  S. Gabriel,et al.  De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly , 2012, Nature Genetics.

[74]  Julie C. Sapp,et al.  Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA , 2012, Nature Genetics.

[75]  J. Shendure,et al.  De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes , 2012, Nature Genetics.

[76]  W. Sellers,et al.  Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations , 2012, Molecular Cancer Therapeutics.

[77]  M. Shackleton,et al.  Physiological Levels of Pik3ca H1047R Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors , 2012, PloS one.

[78]  P. Pandolfi,et al.  The functions and regulation of the PTEN tumour suppressor , 2012, Nature Reviews Molecular Cell Biology.

[79]  L. Platanias,et al.  An overview of the mTOR pathway as a target in cancer therapy , 2012, Expert opinion on therapeutic targets.

[80]  A. Ferrando,et al.  Targeting nonclassical oncogenes for therapy in T-ALL. , 2012, Cancer cell.

[81]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[82]  M. Horton,et al.  Regulation of immune responses by mTOR. , 2012, Annual review of immunology.

[83]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[84]  Eric Meggers,et al.  PIM1 kinase as a target for cancer therapy , 2012, Expert opinion on investigational drugs.

[85]  J. Baselga,et al.  Dual Mtorc1/2 and Her2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-her2 Therapy Statement of Translational Relevance , 2022 .

[86]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[87]  Nicholas T. Ingolia,et al.  The translational landscape of mTOR signalling steers cancer initiation and metastasis , 2012, Nature.

[88]  L. Tran,et al.  Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. , 2012, Cancer research.

[89]  A. Kraft,et al.  Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. , 2012, Cancer research.

[90]  L. Boon,et al.  Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors. , 2012, Cancer research.

[91]  Kylie L. Gorringe,et al.  An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. , 2012, The Journal of clinical investigation.

[92]  L. Platanias,et al.  Targeting AMPK in the treatment of malignancies , 2012, Journal of cellular biochemistry.

[93]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[94]  A. Tolcher,et al.  The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer , 2012, Clinical Cancer Research.

[95]  B. Vanhaesebroeck,et al.  Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor , 2011, The Biochemical journal.

[96]  N. Curtin,et al.  Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K , 2011, Molecular Cancer Therapeutics.

[97]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[98]  J. Thigpen.  Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer , 2012 .

[99]  David Olmos,et al.  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  C. Rommel,et al.  PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic. , 2011, Cancer discovery.

[101]  J. Balko,et al.  Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  W. Curran,et al.  Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells , 2011, Molecular Cancer Therapeutics.

[103]  M. Hall,et al.  Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.

[104]  P. Vogt,et al.  PI3K and STAT3: a new alliance. , 2011, Cancer Discovery.

[105]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[106]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[107]  John E. Burke,et al.  Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases , 2011, Science Signaling.

[108]  M. Keating,et al.  The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. , 2011, Blood.

[109]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[110]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[111]  N. Ilić,et al.  PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis , 2011, Proceedings of the National Academy of Sciences.

[112]  D. Plas,et al.  Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. , 2011, Cancer research.

[113]  Sarat Chandarlapaty,et al.  mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.

[114]  Lewis C Cantley,et al.  The APL paradigm and the "co-clinical trial" project. , 2011, Cancer discovery.

[115]  G. Mills,et al.  High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. , 2011, Cancer discovery.

[116]  C. Ji,et al.  NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia , 2011, Leukemia & lymphoma.

[117]  J. Weiss,et al.  mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. , 2011, Cancer research.

[118]  D. Fruman,et al.  A lipid kinase cousin cooperates to promote cancer. , 2011, Cancer cell.

[119]  P. Foubert,et al.  Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. , 2011, Cancer cell.

[120]  G. Mills,et al.  Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and -independent mechanisms , 2011, Nature Medicine.

[121]  J. McCubrey,et al.  Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia , 2011, Leukemia.

[122]  Qingsheng Li,et al.  A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. , 2011, Immunity.

[123]  L. Crinò,et al.  Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[124]  B. Hennessy,et al.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. , 2011, The Journal of clinical investigation.

[125]  P. Worley,et al.  The mammalian Target of Rapamycin (mTOR) regulates T helper cell differentiation through the selective activation of mTORC1 and mTORC2 signaling , 2011, Nature Immunology.

[126]  V. Sondak,et al.  PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. , 2011, Cancer research.

[127]  Roger L. Williams,et al.  Structure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism , 2011, Molecular cell.

[128]  V. Zinzalla,et al.  Activation of mTORC2 by Association with the Ribosome , 2011, Cell.

[129]  N. Sonenberg,et al.  Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. , 2011, Cancer research.

[130]  J. Oyarzábal,et al.  Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. , 2011, Cancer letters.

[131]  Shikha Khatri,et al.  Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency , 2011, Proceedings of the National Academy of Sciences.

[132]  Sarat Chandarlapaty,et al.  AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. , 2011, Cancer cell.

[133]  Wei Wang,et al.  Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer , 2011, Clinical Cancer Research.

[134]  T. Horvath,et al.  An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. , 2010, Immunity.

[135]  C. James,et al.  Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma , 2010, Science Signaling.

[136]  R. Figlin,et al.  Akt inhibitors in clinical development for the treatment of cancer , 2010, Expert opinion on investigational drugs.

[137]  Justin Chapman,et al.  Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). , 2010, The Biochemical journal.

[138]  P. Vogt,et al.  Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110α , 2010, Proceedings of the National Academy of Sciences.

[139]  Q. She,et al.  4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. , 2010, Cancer cell.

[140]  L. Platanias,et al.  Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells , 2010, Proceedings of the National Academy of Sciences.

[141]  B. Vanhaesebroeck,et al.  Activity of any class IA PI3K isoform can sustain cell proliferation and survival , 2010, Proceedings of the National Academy of Sciences.

[142]  G. Mills,et al.  PI3K pathway-directed therapeutic strategies in cancer. , 2010, Current opinion in investigational drugs.

[143]  B. Vanhaesebroeck,et al.  The emerging mechanisms of isoform-specific PI3K signalling , 2010, Nature Reviews Molecular Cell Biology.

[144]  D. Fruman,et al.  Targeting TOR dependence in cancer , 2010, Oncotarget.

[145]  O. Fernandez-Capetillo,et al.  Nuclear phosphoinositide 3-kinase β controls double-strand break DNA repair , 2010, Proceedings of the National Academy of Sciences.

[146]  Paul Workman,et al.  Drugging the PI3 kinome: from chemical tools to drugs in the clinic. , 2010, Cancer research.

[147]  M. Karin,et al.  B-cell-derived lymphotoxin promotes castration-resistant prostate cancer , 2010, Nature.

[148]  Jing Chen,et al.  Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor , 2010, Nature Medicine.

[149]  Shijie Li,et al.  Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis , 2010, Proceedings of the National Academy of Sciences.

[150]  Ying-Wei Lin,et al.  A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. , 2010, Blood.

[151]  R. Abraham,et al.  Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. , 2010, Cancer research.

[152]  Yi Liu,et al.  The p110δ crystal structure uncovers mechanisms for selectivity and potency of novel PI3K inhibitors , 2009, Nature chemical biology.

[153]  K. Okkenhaug,et al.  PI3Ks in lymphocyte signaling and development. , 2010, Current topics in microbiology and immunology.

[154]  P. Hawkins,et al.  PI3K signaling in neutrophils. , 2010, Current topics in microbiology and immunology.

[155]  Lisa L. Smith,et al.  AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. , 2010, Cancer research.

[156]  K. Shokat,et al.  the p 110 structure : mechanisms for selectivity and potency of new pI ( 3 ) K inhibitors , 2010 .

[157]  J. Pelletier,et al.  Inhibitors of translation initiation as cancer therapeutics. , 2009, Future medicinal chemistry.

[158]  B. Peters,et al.  Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. , 2009, Cancer cell.

[159]  M. Girvin,et al.  Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110α and are disrupted in oncogenic p85 mutants , 2009, Proceedings of the National Academy of Sciences.

[160]  Nadine Cybulski,et al.  TOR complex 2: a signaling pathway of its own. , 2009, Trends in biochemical sciences.

[161]  M. Gold,et al.  Phosphoinositide 3-Kinase p110δ Regulates Natural Antibody Production, Marginal Zone and B-1 B Cell Function, and Autoantibody Responses1 , 2009, The Journal of Immunology.

[162]  D. Lebwohl,et al.  Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy , 2009, Journal of hematology & oncology.

[163]  T. Halazonetis,et al.  Emerging common themes in regulation of PIKKs and PI3Ks , 2009, The EMBO journal.

[164]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[165]  B. Cubelos,et al.  Essential function for the GTPase TC21 in homeostatic antigen receptor signaling , 2009, Nature Immunology.

[166]  P. Worley,et al.  The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. , 2009, Immunity.

[167]  M. Belvin,et al.  Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab , 2009, Clinical Cancer Research.

[168]  Chao Zhang,et al.  Inhibitor Hijacking of Akt Activation , 2009, Nature chemical biology.

[169]  R. Ahmed,et al.  mTOR regulates memory CD8 T cell differentiation , 2009, Nature.

[170]  C. Wagner,et al.  Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. , 2009, ACS chemical biology.

[171]  W. Sellers,et al.  PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. , 2009, Cancer research.

[172]  A. Thomson,et al.  Immunoregulatory functions of mTOR inhibition , 2009, Nature Reviews Immunology.

[173]  F. Giles,et al.  The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents , 2009, Targeted Oncology.

[174]  D. Fruman,et al.  Fine tuning the immune response with PI3K , 2009, Immunological reviews.

[175]  D. Guertin,et al.  mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. , 2009, Cancer cell.

[176]  M. Loda,et al.  Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis , 2009, Science Signaling.

[177]  Lisa S. Chen,et al.  Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. , 2008, Blood.

[178]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[179]  K. Shokat,et al.  A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. , 2008, The Biochemical journal.

[180]  W. Sellers,et al.  Drug discovery approaches targeting the PI3K/Akt pathway in cancer , 2008, Oncogene.

[181]  K. Shokat,et al.  Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. , 2008, The Journal of clinical investigation.

[182]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[183]  Alice T. Loo,et al.  PTEN-deficient cancers depend on PIK3CB , 2008, Proceedings of the National Academy of Sciences.

[184]  W. Gerald,et al.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. , 2008, The Journal of clinical investigation.

[185]  Paul Workman,et al.  Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. , 2008, Current opinion in pharmacology.

[186]  M. Loda,et al.  Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis , 2008, Nature.

[187]  B. Manning,et al.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. , 2008, The Biochemical journal.

[188]  Pier Paolo Pandolfi,et al.  Tenets of PTEN Tumor Suppression , 2008, Cell.

[189]  Suzanne F. Jones,et al.  Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  Robert A Copeland,et al.  Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. , 2008, Cancer research.

[191]  M. Lemmon,et al.  Membrane recognition by phospholipid-binding domains , 2008, Nature Reviews Molecular Cell Biology.

[192]  Guang Yao,et al.  Sensing and Integration of Erk and PI3K Signals by Myc , 2008, PLoS Comput. Biol..

[193]  Vincent J Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[194]  Bernd Giese,et al.  Targeting phosphoinositide 3-kinase: moving towards therapy. , 2008, Biochimica et biophysica acta.

[195]  S. Lowe,et al.  Dissecting eIF4E action in tumorigenesis. , 2007, Genes & development.

[196]  Bert Vogelstein,et al.  The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations , 2007, Science.

[197]  F. Khuri,et al.  Inhibition of Mammalian Target of Rapamycin Induces Phosphatidylinositol 3-Kinase-Dependent and Mnk-Mediated Eukaryotic Translation Initiation Factor 4E Phosphorylation , 2007, Molecular and Cellular Biology.

[198]  P. Pandolfi,et al.  Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. , 2007, Cancer research.

[199]  A. Maity,et al.  Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation* , 2007, Journal of Biological Chemistry.

[200]  S. Knapp,et al.  Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. , 2007, Cancer research.

[201]  Yuval Inbar,et al.  Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit , 2007, Science.

[202]  G. Stamp,et al.  Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice , 2007, Cell.

[203]  M. Zvelebil,et al.  Exploring the specificity of the PI3K family inhibitor LY294002. , 2007, The Biochemical journal.

[204]  K. Okkenhaug,et al.  Antigen receptor signalling: a distinctive role for the p110δ isoform of PI3K , 2007, Trends in immunology.

[205]  A. Degterev,et al.  Small-Molecule Inhibition of the Interaction between the Translation Initiation Factors eIF4E and eIF4G , 2007, Cell.

[206]  K. Okkenhaug,et al.  Antigen receptor signalling : a distinctive role for the p 110 d isoform of PI 3 K , 2007 .

[207]  Bert Vogelstein,et al.  The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. , 2007, Science.

[208]  T. Roberts,et al.  PI3 Kinases in Cancer: From Oncogene Artifact to Leading Cancer Target , 2006, Science's STKE.

[209]  Phillip T. Hawkins,et al.  Gβγs and the Ras binding domain of p110γ are both important regulators of PI3Kγ signalling in neutrophils , 2006, Nature Cell Biology.

[210]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[211]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[212]  A. Look,et al.  Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia , 2006, Nature Reviews Cancer.

[213]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[214]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[215]  Y. Samuels,et al.  Oncogenic PI3K and its role in cancer , 2006, Current opinion in oncology.

[216]  G. Collins.  The next generation. , 2006, Scientific American.

[217]  Paul Tempst,et al.  Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.

[218]  Steven P Gygi,et al.  Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[219]  K. Okkenhaug,et al.  Cutting Edge: Differential Roles for Phosphoinositide 3-Kinases, p110γ and p110δ, in Lymphocyte Chemotaxis and Homing1 , 2004, The Journal of Immunology.

[220]  F. McCormick,et al.  Signaling Specificity by Ras Family GTPases Is Determined by the Full Spectrum of Effectors They Regulate , 2004, Molecular and Cellular Biology.

[221]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[222]  D. Fruman.  Towards an understanding of isoform specificity in phosphoinositide 3-kinase signalling in lymphocytes. , 2004, Biochemical Society transactions.

[223]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[224]  H. Gram,et al.  Negative Regulation of Protein Translation by Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 , 2001, Molecular and Cellular Biology.

[225]  K. Kaestner,et al.  Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ) , 2001 .

[226]  T. Seufferlein,et al.  Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. , 2001, Cancer research.

[227]  M. Waterfield,et al.  Synthesis and function of 3-phosphorylated inositol lipids. , 2001, Annual review of biochemistry.

[228]  D J Glass,et al.  Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. , 1999, Science.

[229]  K. Moelling,et al.  Phosphorylation and regulation of Raf by Akt (protein kinase B). , 1999, Science.

[230]  Christian Ried,et al.  Structural insights into phosphoinositide 3-kinase catalysis and signalling , 1999, Nature.

[231]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[232]  R. Abraham,et al.  Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3‐kinase inhibitors, wortmannin and LY294002. , 1996, The EMBO journal.

[233]  J. Testa,et al.  A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. , 1991, Science.

[234]  J J Thompson,et al.  The new alliance. , 2018, The New Zealand nursing journal. Kai tiaki.